These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8796584)

  • 1. Preliminary clinical experience with AMI 227.
    McLachlan SJ; Morris M; Lucas MA; Baum LM
    Acad Radiol; 1996 Aug; 3 Suppl 2():S295-6. PubMed ID: 8796584
    [No Abstract]   [Full Text] [Related]  

  • 2. Experimental investigation of the delivery pathway of ultrasmall superparamagnetic iron oxide to lymph nodes.
    Frija G; Clément O; Le Guen O; Cuénod CA; Siauve N; Benderbous S
    Acad Radiol; 1996 Aug; 3 Suppl 2():S299-300. PubMed ID: 8796586
    [No Abstract]   [Full Text] [Related]  

  • 3. MR lymphography: evidence of extravasation of superparamagnetic nanoparticles into the lymph.
    Clement O; Rety F; Cuenod CA; Siauve N; Carnot F; Bordat C; Siche M; Frija G
    Acad Radiol; 1998 Apr; 5 Suppl 1():S170-2; discussion S183-4. PubMed ID: 9561073
    [No Abstract]   [Full Text] [Related]  

  • 4. [Use of ultrasmall ferric oxide (Sinerem) particles as a magnetic resonance contrast substance for imaging lymph nodal metastases in cancer of the head and neck].
    Sviridov NK; Napolov IuK; Bolotova EN; Iakobs LV
    Vestn Rentgenol Radiol; 2004; (3):63-4. PubMed ID: 15587888
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of superparamagnetic iron oxide (AMI-25) on liver and spleen imaging using spin-echo and fast spin-echo magnetic resonance pulse sequences.
    Schwartz LH; Seltzer SE; Adams DF; Tempany CM; Piwnica-Worms DR; Silverman SG; Herman L; Herman LT; Hooshmand R
    Invest Radiol; 1994 Jun; 29 Suppl 2():S21-3. PubMed ID: 7928234
    [No Abstract]   [Full Text] [Related]  

  • 6. Overview of contrast enhancement with iron oxides.
    Frija G; Clément O; de Kerviler E
    Invest Radiol; 1994 Jun; 29 Suppl 2():S75-7. PubMed ID: 7928276
    [No Abstract]   [Full Text] [Related]  

  • 7. [Overview of MRI contrast media. The case of endorem].
    Duroux M
    Radiologe; 1995 Nov; 35(11 Suppl 2):S247-8. PubMed ID: 8588029
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of the time window for Resovist-enhanced T2-weighted MRI of the liver.
    Reimer P; Müller M; Marx C; Balzer T
    Acad Radiol; 2002 Aug; 9 Suppl 2():S336-8. PubMed ID: 12188267
    [No Abstract]   [Full Text] [Related]  

  • 9. The pharmacokinetics of the lymphotropic nanoparticle MRI contrast agent ferumoxtran-10.
    Islam T; Wolf G
    Cancer Biomark; 2009; 5(2):69-73. PubMed ID: 19414923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic signal intensity changes in liver with superparamagnetic MR contrast agents.
    Reimer P; Kwong KK; Weisskoff R; Cohen MS; Brady TJ; Weissleder R
    J Magn Reson Imaging; 1992; 2(2):177-81. PubMed ID: 1562768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biodistribution of an ultrasmall superparamagnetic iron oxide colloid, BMS 180549, by different routes of administration.
    Bengele HH; Palmacci S; Rogers J; Jung CW; Crenshaw J; Josephson L
    Magn Reson Imaging; 1994; 12(3):433-42. PubMed ID: 8007773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Splenic imaging with ultrasmall superparamagnetic iron oxide ferumoxtran-10 (AMI-7227): preliminary observations.
    Harisinghani MG; Saini S; Weissleder R; Rubin D; deLange E; Harms S; Weinreb J; Small W; Sukerkar A; Brown JJ; Zelch J; Lucas M; Morris M; Hahn PF
    J Comput Assist Tomogr; 2001; 25(5):770-6. PubMed ID: 11584239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evaluation of ultrasmall superparamagnetic iron oxide particles for liver imaging.
    Saini S; Edelman RR; Li W; Petersein J; Hahn PF
    Acad Radiol; 1996 Aug; 3 Suppl 2():S409-12. PubMed ID: 8796616
    [No Abstract]   [Full Text] [Related]  

  • 14. Superparamagnetic nanoparticles as blood-pool contrast agents. Contribution to MRI preclinical investigations.
    Benderbous S; Bonnemain B
    Radiologe; 1995 Nov; 35(11 Suppl 2):S248-52. PubMed ID: 8588030
    [No Abstract]   [Full Text] [Related]  

  • 15. Dose-dependency and rate of decay of efficacy of Resovist on MR images in a rat cirrhotic liver model.
    Kato N; Takahashi M; Tsuji T; Ihara S; Brautigam M; Miyazawa T
    Invest Radiol; 1999 Sep; 34(9):551-7. PubMed ID: 10485069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of spatial distribution in proton relaxation enhancement by particulate iron oxide.
    Tanimoto A; Yuasa Y; Stark DD
    Invest Radiol; 1994 Jun; 29 Suppl 2():S78-80. PubMed ID: 7523329
    [No Abstract]   [Full Text] [Related]  

  • 17. Contrast-enhanced MR imaging of liver and spleen: first experience in humans with a new superparamagnetic iron oxide.
    Hamm B; Staks T; Taupitz M; Maibauer R; Speidel A; Huppertz A; Frenzel T; Lawaczeck R; Wolf KJ; Lange L
    J Magn Reson Imaging; 1994; 4(5):659-68. PubMed ID: 7981510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of superparamagnetic iron-oxide MR contrast agents in the rat.
    Majumdar S; Zoghbi SS; Gore JC
    Invest Radiol; 1990 Jul; 25(7):771-7. PubMed ID: 2391194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biodegradation of magnetite dextran nanoparticles in the rat. A histologic and biophysical study.
    Okon E; Pouliquen D; Okon P; Kovaleva ZV; Stepanova TP; Lavit SG; Kudryavtsev BN; Jallet P
    Lab Invest; 1994 Dec; 71(6):895-903. PubMed ID: 7807971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MR lymphography using iron oxide nanoparticles in rats: pharmacokinetics in the lymphatic system after intravenous injection.
    Réty F; Clément O; Siauve N; Cuénod CA; Carnot F; Sich M; Buisine A; Frija G
    J Magn Reson Imaging; 2000 Nov; 12(5):734-9. PubMed ID: 11050643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.